Sugammadex + Neostigmine/Glycopyrrolate
ApprovedTerminated 0 watching 0 views this week🔥 Hot
85
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Pulmonary Complications
Conditions
Pulmonary Complications
Trial Timeline
Dec 3, 2018 → Jan 1, 2021
NCT ID
NCT02825576About Sugammadex + Neostigmine/Glycopyrrolate
Sugammadex + Neostigmine/Glycopyrrolate is a approved stage product being developed by Merck for Pulmonary Complications. The current trial status is terminated. This product is registered under clinical trial identifier NCT02825576. Target conditions include Pulmonary Complications.
Hype Score Breakdown
Clinical
30
Activity
20
Company
10
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02825576 | Approved | Terminated |
Competing Products
20 competing products in Pulmonary Complications